AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01341392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodiopine
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study NCT01341392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 amlodipine
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study NCT02346890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Study NCT02346890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Study NCT01488344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple kinase inhibitor BIBF1120
Description: triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
Study NCT00061282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clotrimazole
Description: One retention enema, administered nightly
Study NCT00061282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: One retention enema, administered nightly
Study NCT03139513 — intervention group
Intervention type: DRUG
Intervention: Cobimetinib
Description: Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
Study NCT02781974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
Study NCT03755622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transpalatal Arch (TPA)
Description: In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
Study NCT04504058 — intervention group
Intervention type: OTHER
Intervention: routine clinical treatment
Description: Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
Study NCT01962168 — intervention group
Intervention type: DEVICE
Intervention: Evolution® Biliary Stent - Uncovered
Description: Commercially available device
Study NCT00701623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: patients will receive the application of one of two types of heparin directly on the injured area
Study NCT03755622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpalatal Arch (TPA) fabricated from 3D reconstructed model
Description: In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
Study NCT03677674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Participants will be dehydrated (2% of their body weight) using sauna.
Study NCT01973283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medication
Description: If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
Study NCT03139513 — intervention group
Intervention type: DRUG
Intervention: Vemurafenib
Description: Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
Study NCT01101100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: 210 mg SC or 140 mg SC
Study NCT03881371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
Study NCT03881371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
Study NCT00701623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folder water
Description: patients will receive the application of folder water directly on the injured area
Study NCT02068768 — intervention group
Intervention type: DEVICE
Intervention: Avenue® L Interbody Fusion System (LDR Spine)
Description: PEEK, intervertebral cage for interbody fusion of the lumbar spine
Study NCT01216371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
Study NCT01216371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Study NCT00344942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
Study NCT00344942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a double spray into each nostril once daily
Study NCT03460015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped).
Study NCT03460015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.
Study NCT03460015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.
Study NCT02674854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%/0.005%
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Study NCT02674854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) ophthalmic solution 0.02%
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Study NCT02674854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Study NCT02014870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:1000 Live wild-type A/California/H1N1 2009
Description: 1:1000 dilution of neat virus
Study NCT02014870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:100 Live wild-type A/California/H1N1 2009
Description: 1:100 dilution of neat virus
Study NCT02014870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:10 Live wild-type A/California/H1N1 2009
Description: 1:10 dilution of neat virus
Study NCT01622283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine
Study NCT04700267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 film-coated tablet
Description: GLPG3970 for oral administration
Study NCT04700267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film-coated tablet
Description: Placebo for oral administration
Study NCT03095092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 400 mg
Description: 4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
Study NCT01475955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad Area ALA 1-hour incubation
Description: 20% ALA, broad area, 1 hour incubation
Study NCT01622283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Cetirizine
Study NCT02735499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinum toxin A
Description: Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
Study NCT03970408 — intervention group
Intervention type: PROCEDURE
Intervention: MNT1
Description: Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping.
Study NCT00510965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection ranibizumab
Description: Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
Study NCT04572360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Exercise
Description: Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
Study NCT01420744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT086
Description: BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period.
Study NCT04572360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Bai He Gu Jin Tang
Description: The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
Study NCT01753050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke volume monitoring
Description: Pulse contour stroke volume monitoring
Study NCT03812627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter
Study NCT03812627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter
Study NCT03812627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autopsy
Description: Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
Study NCT03812627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autopsy
Description: Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
Study NCT01420744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Human Albumin infusion
Description: 1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
Study NCT01823900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
Study NCT03295565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel 25mg/m2 IV, once every 3 weeks
Study NCT03295565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
Study NCT03295565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160mg oral taken daily
Study NCT03073551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wii Group
Description: Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
Study NCT01823900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation
Description: Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
Study NCT03033888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health-Literacy Focused Education Session
Study NCT04181788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
Study NCT00212017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voglibose
Study NCT00212017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and exercise therapy
Study NCT03189381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
Study NCT03189381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
Study NCT01711060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Study NCT01711060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon catheter
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: oral, bis in diem/twice a day (bid)
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid (MPA)
Description: 2 oral capsules of mycophenolic acid 360mg administered bid
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A (CsA)
Description: CsA dose adjustments were based on CsA trough levels (C0).
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: CsA dose adjustments were based on CsA trough levels (C0).
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Study NCT00251004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Study NCT04232709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared electronic patient record
Description: MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
Study NCT00887744 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aperius® Percutaneous Interspinous Spacer
Description: Implantation of the Aperius® device
Study NCT03936452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
Study NCT02508298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG
Description: HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
Study NCT02508298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Retention test
Description: As decribed in arm descriptions
Study NCT02508298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liver stiffness measurement
Description: As decribed in arm descriptions; perfromed by ARFI
Study NCT02508298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spleen stiffness measurement
Description: As decribed in arm descriptions; performed by ARFI
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo sitagliptin
Description: Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo sitagliptin
Description: Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo metformin
Description: Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
Study NCT00830076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo metformin
Description: Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.